Reacquisition of RAI Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244: A Pilot Study.
Phase of Trial: Phase II
Latest Information Update: 17 Apr 2017
At a glance
- Drugs Selumetinib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 10 Apr 2013 Planned End Date changed from 1 Sep 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.
- 10 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.